Devano and Verge form strategic partnership

Verge Genomics is a clinical-stage biotech company using human data and machine learning to transform how drugs are discovered and developed. Their platform, CONVERGE®, integrates genomics, human genetics, ML, and advanced disease modeling to identify biological pathways and targets that are most likely to be disease-modifying.

Rather than relying solely on reductionist models, Verge starts with human tissue and genetics, using systems biology and AI to synthesize evidence and prioritize targets with strong disease causality. They’ve also invested deeply in experimental capabilities—iPSC-derived human cell and organoid models, drug screening, medicinal chemistry—to build a fully integrated drug discovery engine.

Read the full press release at Devano.ai